South Korean-based biotechnology company announced that its Sabin-Inactivated Polio Vaccine (Sabin-IPV) Eupolio™ is the first to receive the World Health Organization (WHO) prequalification be supplied globally.
LG Chem stated in a press release, ‘Eupolio demonstrated excellent phase III results in 2019, inducing high antibody titers against both wild-type and Sabin polioviruses, which will also protect against circulating vaccine-derived polioviruses (cVDPV) that make up the majority of polio cases in recent years.’
Read More
